Zealand Pharma A/S (LON:0NZU)

Zealand Pharma Statistics

Total Valuation

Zealand Pharma has a market cap or net worth of GBP 2.93 billion. The enterprise value is 1.22 billion.

Market Cap	2.93B
Enterprise Value	1.22B

Important Dates

The last earnings date was Thursday, February 19, 2026.

Earnings Date	Feb 19, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	70.61M
Shares Outstanding	n/a
Shares Change (YoY)	+7.70%
Shares Change (QoQ)	+0.08%
Owned by Insiders (%)	0.36%
Owned by Institutions (%)	38.06%
Float	56.80M

Valuation Ratios

The trailing PE ratio is 3.89 and the forward PE ratio is 30.60.

PE Ratio	3.89
Forward PE	30.60
PS Ratio	2.72
PB Ratio	1.69
P/TBV Ratio	1.70
P/FCF Ratio	3.86
P/OCF Ratio	3.84
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 1.51, with an EV/FCF ratio of 1.61.

EV / Earnings	1.62
EV / Sales	1.14
EV / EBITDA	1.51
EV / EBIT	1.51
EV / FCF	1.61

Financial Position

The company has a current ratio of 23.57, with a Debt / Equity ratio of 0.03.

Current Ratio	23.57
Quick Ratio	23.20
Debt / Equity	0.03
Debt / EBITDA	0.06
Debt / FCF	0.06
Interest Coverage	238.04

Financial Efficiency

Return on equity (ROE) is 55.06% and return on invested capital (ROIC) is 1,401.57%.

Return on Equity (ROE)	55.06%
Return on Assets (ROA)	33.97%
Return on Invested Capital (ROIC)	1,401.57%
Return on Capital Employed (ROCE)	45.26%
Weighted Average Cost of Capital (WACC)	7.32%
Revenue Per Employee	2.19M
Profits Per Employee	1.54M
Employee Count	501
Asset Turnover	0.72
Inventory Turnover	n/a

Taxes

In the past 12 months, Zealand Pharma has paid 63.78 million in taxes.

Income Tax	63.78M
Effective Tax Rate	7.80%

Stock Price Statistics

The stock price has decreased by -45.53% in the last 52 weeks. The beta is 0.56, so Zealand Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.56
52-Week Price Change	-45.53%
50-Day Moving Average	417.63
200-Day Moving Average	430.76
Relative Strength Index (RSI)	34.70
Average Volume (20 Days)	15,423

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Zealand Pharma had revenue of GBP 1.08 billion and earned 753.99 million in profits. Earnings per share was 10.54.

Revenue	1.08B
Gross Profit	1.08B
Operating Income	807.97M
Pretax Income	817.78M
Net Income	753.99M
EBITDA	809.13M
EBIT	807.97M
Earnings Per Share (EPS)	10.54

Balance Sheet

The company has 1.76 billion in cash and 47.40 million in debt, with a net cash position of 1.72 billion.

Cash & Cash Equivalents	1.76B
Total Debt	47.40M
Net Cash	1.72B
Net Cash Per Share	n/a
Equity (Book Value)	1.73B
Book Value Per Share	24.53
Working Capital	1.75B

Cash Flow

In the last 12 months, operating cash flow was 762.98 million and capital expenditures -3.90 million, giving a free cash flow of 759.08 million.

Operating Cash Flow	762.98M
Capital Expenditures	-3.90M
Free Cash Flow	759.08M
FCF Per Share	n/a

Margins

Gross margin is 99.99%, with operating and profit margins of 75.06% and 70.05%.

Gross Margin	99.99%
Operating Margin	75.06%
Pretax Margin	75.98%
Profit Margin	70.05%
EBITDA Margin	75.17%
EBIT Margin	75.06%
FCF Margin	70.52%

Dividends & Yields

Zealand Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.70%
Shareholder Yield	-7.70%
Earnings Yield	25.71%
FCF Yield	25.88%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Zealand Pharma has an Altman Z-Score of 21.93 and a Piotroski F-Score of 7.

Altman Z-Score	21.93
Piotroski F-Score	7